Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older (Q35023437)

5 August 2017

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older (English)

1 reference

5 August 2017

1 reference

Andrew N Freedman

1

1 reference

5 August 2017

Binbing Yu

2

1 reference

5 August 2017

Mitchell H Gail

3

1 reference

5 August 2017

Joseph P Costantino

4

1 reference

5 August 2017

Barry I Graubard

5

1 reference

5 August 2017

Victor G Vogel

6

1 reference

5 August 2017

Garnet L Anderson

7

1 reference

5 August 2017

Worta McCaskill-Stevens

8

1 reference

5 August 2017

language of work or name

English

0 references

publication date

2 May 2011

1 reference

Journal of Clinical Oncology

5 August 2017

1 reference

5 August 2017

29

1 reference

5 August 2017

2327-2333

1 reference

5 August 2017

17

1 reference

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Projecting individualized absolute invasive breast cancer risk in African American women

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107748

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

25 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21537036

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21537036

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21537036

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2010.33.0258

1 reference

5 August 2017

1 reference

5 August 2017

1 reference